Skip to main content
Premium Trial:

Request an Annual Quote

GenPath Women's Health ClariTest

GenPath Women's Health, a business unit of BioReference Laboratories, is offering ClariTest, a noninvasive prenatal test that will be initially performed at Illumina. The test leverages massively parallel sequencing technology to screen for trisomies 13, 18, and 21, and sex chromosome abnormalities. It also offers the option to screen for five microdeletions, including 22q11.2, or DiGeorge syndrome. The company said that it will ultimately develop and validate its own laboratory-developed NIPT using Illumina technology.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.